Clinical trials
Primary CNS Lymphoma clinical trials
Below are recruiting primary cns lymphoma clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07749365RecruitingPhase 2
Combination therapy for newly diagnosed brain lymphoma
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
Xiamen, FujianAges 18 years+ - NCT05351593RecruitingPhase 1/Phase 2
Tafasitamab and lenalidomide for returning CNS lymphoma
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
San Francisco, CaliforniaAges 18 years+ - NCT04609046RecruitingPhase 1
Lenalidomide and nivolumab added to standard treatment for brain lymphoma
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
Los Angeles, CaliforniaAges 18 years+ - NCT06940791RecruitingPhase 2
Tirabrutinib vs placebo for CNS lymphoma in remission
This trial tests whether taking the drug tirabrutinib (a pill) can help keep primary CNS lymphoma from coming back after successful initial chemotherapy. It compares the drug to a placebo (a dummy pill).
TokyoAges 18 years+ - NCT07082868RecruitingPhase 1
Study of epcoritamab and ibrutinib for central nervous system lymphoma
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT06730542RecruitingPhase 1
Zanubrutinib plus pola-R-CHP and high-dose methotrexate for secondary CNS lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
Miami, FloridaAges 18 years+ - NCT06946407Recruiting
Chemotherapy combination for brain lymphoma
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
ChangchunAges Up to 60 years - NCT06931652RecruitingPhase 2
Epcoritamab with lenalidomide and rituximab for CNS lymphoma
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
BordeauxAges 18 years+ - NCT04656431RecruitingPhase 1
Hyperpolarized imaging for CNS lymphoma
This trial tests a new type of imaging scan to see if it can better detect and monitor brain lymphoma. It may help doctors tailor treatment by seeing how the cancer responds early on.
San Francisco, CaliforniaAges 18 years+ - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT04006561Recruiting
Brain lymphoma study using targeted whole-brain radiation
This trial studies how newly diagnosed primary central nervous system (brain) non-Hodgkin lymphoma responds to a specific type of radiation to the whole brain, and it also looks at changes in thinking, mood, and behavior. It may help doctors understand how this treatment affects day-to-day brain function.
TaoyuanAges 18–80 - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT05998642RecruitingPhase 2
Ibrutinib combo for newly diagnosed brain lymphoma
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Calgary, AlbertaAges 18 years+ - NCT07062627RecruitingPhase 2
CAR-T cell therapy for CNS lymphoma
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
SeoulAges 19 years+ - NCT07137494RecruitingPhase 1
CAR T-cell therapy for CNS lymphoma
This trial tests a new type of CAR T-cell therapy (MB-CART19.1) for people with central nervous system lymphoma (CNSL) that has come back or not responded to treatment. It aims to see if this therapy can help treat the lymphoma in the brain or spinal fluid.
Basking Ridge, New JerseyAges 18 years+ - NCT06132737RecruitingPhase 1/Phase 2
Targeted radiation therapy for brain lymphoma
This trial tests a new targeted radiation therapy for lymphoma that has spread to the brain or spinal cord and has not responded to other treatments. The treatment uses a radioactive molecule (yttrium-90) attached to a substance that homes in on a specific marker (CXCR4) on the lymphoma cells, aiming to destroy them while limiting damage to healthy tissue.
Munich, BavariaAges 18–120 - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT06755619Recruiting
ctDNA testing for response in first-line PCNSL treatment
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
HelsinkiAges 18–70 - NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Phoenix, ArizonaAges 18 years+ - NCT06784726RecruitingPhase 2
Odronextamab before CAR-T for large B-cell lymphoma
This trial tests a drug called odronextamab for people with large B-cell lymphoma whose cancer did not respond to or came back after initial treatment. The goal is to see if odronextamab can help shrink the tumor before getting CAR-T cell therapy.
Seattle, WashingtonAges 18 years+
Hear when a new Primary CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary cns lymphoma?
- Yes. Clin2 currently lists 73 recruiting primary cns lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary cns lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary cns lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Primary CNS Lymphoma (PCNSL)
- Primary Central Nervous System (CNS) Lymphoma
- Primary Central Nervous System Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- CNS Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.